New Analyst Forecast: $GILD Given $135.0 Price Target

Recent analyst ratings for $GILD show a median price target of $126, with Morgan Stanley's Terence Flynn setting a high target of $135. Congressional members have actively traded $GILD, with 6 purchases and 2 sales in the last six months, while insider trading activity reveals 16 sales and no purchases, including significant sales by the CFO. Institutional investors show mixed sentiment, with FMR LLC adding over 18 million shares while Capital World Investors reduced their position by a similar amount in Q1 2025.

Analysis

Gilead Sciences ($GILD) presents a mixed technical and sentiment picture. Analyst coverage in the last six months includes five price targets with a median of $126.0, notably influenced by Morgan Stanley's recent $135.0 target, while RBC Capital offers a more conservative $83.0. Congressional trading activity shows a net positive sentiment, with 6 purchases against 2 sales in the past six months, including notable purchases by Representatives Marjorie Taylor Greene (up to $45,000) and Jefferson Shreve (up to $50,000). Conversely, insider transactions paint a bearish picture, with 16 sales and zero purchases over the same period. Significant sales were executed by CFO Andrew D. Dickinson (312,785 shares for ~$31.6M), CCO Johanna Mercier (31,000 shares for ~$3.3M), and CEO Daniel Patrick O'Day (10,000 shares for ~$1.1M). Institutional holdings reflect this divergence: while 934 institutions added shares, 1,008 decreased positions in the most recent quarter. FMR LLC significantly increased its stake by 18.2 million shares (+45.2%), and T. Rowe Price Associates added 11.2 million shares (+314.6%). However, Capital World Investors reduced its holding by 18.2 million shares (-25.3%), and Wellington Management Group cut 8.3 million shares (-23.3%). The overall sentiment score for $GILD is strongly negative (-0.7), despite a moderate market impact score (0.6), underscoring the conflicting signals investors face.

Key Decisions for Investors

• Investors should weigh the optimistic analyst price targets, particularly Morgan Stanley's $135, against the considerable insider selling pressure, especially from key executives like the CFO and CEO.
• Monitor ongoing institutional investor activity closely, as the large, opposing moves by major firms like FMR LLC and Capital World Investors suggest a lack of consensus and potential volatility for $GILD.
• Given the high volume of insider sales and the strongly negative sentiment score, exercise caution and consider if the current risk-reward profile aligns with individual investment strategies, despite some positive signals from congressional trading and certain analyst upgrades.